This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a recent issue of the ARCHIVES,¹ we reported lower fracture risk among women taking 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) for hypercholesterolemia. The research was prompted by the finding that statins increase bone morphogenetic protein-2, leading to osteoblast differentiation and bone formation.² The substantial 60% reduction in fracture risk we reported persisted after adjusting for potential confounders and was greater than expected from increases observed in bone mineral density alone.

Recent data from Britain³ and Australia⁴ support a role for statins in preventing age-related macular degeneration. The authors suggest that statins might prevent the accumulation of basal linear deposit in the Bruch membrane, protect the retina from oxidative damage, and maintain a competent vascular supply to the macula.³ Statins have also been reported to protect against dementia, which may be explained, at least in part, by the protective effect of statins on vascular disorders.⁵ Given that poor vision and . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Commentary: Statins and fracture risk--unresolved questions.
Meier
Int J Epidemiol 2006;35:1308-1309.
FULL TEXT